Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST: Litifilimab in Subacute and Chronic Cutaneous Lupus Erythematosus
jRCT2031230262Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in subacute cutaneous lupus erythematosus (SCLE), cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing Litifilimab (BIIB059) with Placebo (2 arms). Primary endpoints: Part A: Proportion of participants with CLA-IGA-R Erythema score 0 or 1 at Week 16, Part B (US): Proportion of participants with CLA-IGA-R Erythema score 0 or 1 at Week 16 and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
litifilimab
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031230262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230262.